Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem

References

• Stupp R, Mason WP, van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Tosoni A, Franceschi E, Poggi R, et al. Relapsed glioblastoma: treatment strategies for initial and subsequent recurrences. Curr Treat Options Oncol. 2016 Sep;17(9):49.
   PubMed Web of Science ®Google Scholar
• Brandes AA, Gil-Gil M, Saran F, et al. A randomized Phase II Trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma. Oncologist. 2019 Apr;24(4):521–528.
   PubMed Web of Science ®Google Scholar
• Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954–1963.
   PubMed Web of Science ®Google Scholar
• Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019 Sep;20(9):1100–1109.
   PubMed Web of Science ®Google Scholar
• Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov;16(15):e534–e542.
   PubMedGoogle Scholar
• Nayak L, DeAngelis LM, Brandes AA, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017 May 1;19(5):625–635.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Brandes AA, Omuro A, et al. Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the checkMate 143 Phase 3 randomized clinical trial. JAMA Oncol. 2020 Jul 1;6(7):1003–1010.
   PubMed Web of Science ®Google Scholar
• Ricklefs FL, Alayo Q, Krenzlin H, et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018 Mar;4(3):eaar2766.
   PubMed Web of Science ®Google Scholar
• Adhikaree J, Moreno-Vicente J, and Kaur AP, et al. Resistance mechanisms and barriers to successful immunotherapy for treating glioblastoma. Cells. 2020 Jan 21;9(2)263.
   PubMed Web of Science ®Google Scholar
• Kmiecik J, Poli A, Brons NH, et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013 Nov 15;264(1–2):71–83.
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, et al. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clin Cancer Res. 2015 Sep 15;21(18):4062–4072.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-Cell therapy. N Engl J Med. 2016 Dec 29;375(26):2561–2569.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 Jan 15;16(2):474–485.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, and Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017 Jul 19;9(399):eaaa0984.
   PubMed Web of Science ®Google Scholar
• Goff SL, Morgan RA, Yang JC, et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother. 2019 May;42(4):126–135.
   PubMed Web of Science ®Google Scholar
• Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014 Jun 20;344(6190):1396–1401.
   PubMed Web of Science ®Google Scholar
• Neftel C, Laffy J, Filbin MG, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019 Aug 8;178(4):835–849.e21.
   PubMed Web of Science ®Google Scholar
• Perrin SL, Samuel MS, Koszyca B, et al. Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments. Biochem Soc Trans. 2019 Apr 30;47(2):625–638.
   PubMedGoogle Scholar
• Schuster J, Lai RK, Recht LD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun;17(6):854–861.
   PubMed Web of Science ®Google Scholar
• Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1373–1385.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Dho YS, Ock CY, et al. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma. J Neurooncol. 2019 Jun;143(2):321–328.
   PubMed Web of Science ®Google Scholar
• Fang HY, Hughes R, Murdoch C, et al. Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood. 2009 Jul 23;114(4):844–859.
   PubMed Web of Science ®Google Scholar
• Howie D, Waldmann H, Cobbold S. Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment. Front Immunol. 2014;5:409.
   PubMed Web of Science ®Google Scholar
• Agrawal NS, Miller R Jr., and Lal R, et al. Current studies of immunotherapy on Glioblastoma. J Neurol Neurosurg. 2014 Apr 5;1(1):21000104.
   PubMedGoogle Scholar
• Hegde PS, Karanikas V, Evers S. The Where, the When, and the How of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016 Apr 15;22(8):1865–1874.
   PubMed Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015 Apr 3;348(6230):74–80.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017 Jul;14(7):399–416.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Ohnishi K, Kuratsu J, et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008 Sep;216(1):15–24.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12;123(24):3750–3759.
   PubMed Web of Science ®Google Scholar
• Upreti D, Bakhshinyan D, Bloemberg D, et al. Strategies to enhance the efficacy of T-Cell therapy for central nervous system tumors. Front Immunol. 2020;11:599253.
   PubMed Web of Science ®Google Scholar
• Yoo HJ, Harapan BN. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. Immunol Res. 2021 Sep 23.
   PubMed Web of Science ®Google Scholar
• Liu J, Shen L, Tang G, et al. Multiple extracranial metastases from glioblastoma multiforme: a case report and literature review. J Int Med Res. 2020 Jun;48(6):300060520930459.
   PubMed Web of Science ®Google Scholar
• Sridhar P, and Petrocca F. Regional delivery of chimeric antigen receptor (CAR) T-Cells for cancer therapy. Cancers (Basel). 2017 Jul 18;9(7):92.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010 Apr;18(4):843–851.
   PubMed Web of Science ®Google Scholar
• Hombach A, Wieczarkowiecz A, Marquardt T, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol. 2001 Dec 1;167(11):6123–6131.
   PubMed Web of Science ®Google Scholar
• Chen D, Yang J. Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies. Transl Res. 2017 Sep;187:11–21.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011 Aug 10;3(95):95ra73.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720–724.
   PubMed Web of Science ®Google Scholar
• Hartmann J, Schüßler-Lenz M, Bondanza A, et al. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017. 9. Sep(9):1183–1197.
   Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018 Jul 5;379(1):64–73.
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhao L, Zhang Y, et al. Understanding the mechanisms of resistance to CAR T-Cell therapy in malignancies. Front Oncol. 2019;9:1237.
   PubMed Web of Science ®Google Scholar
• Salter AI, Ivey RG, Kennedy JJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018 Aug 21;11:544.
   Web of Science ®Google Scholar
• Zhao Z, Condomines M, van der Stegen SJC, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015 Oct 12;28(4):415–428.
   PubMed Web of Science ®Google Scholar
• Schmidts A, Maus MV. Making CAR T Cells a Solid Option for Solid Tumors. Front Immunol. 2018;9:2593.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Osborn MJ, and Tolar J, et al. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-In CAR-T. Int J Mol Sci. 2018 Jan 24;19(2):340.
   Web of Science ®Google Scholar
• Land CA, Musich PR, Haydar D, et al. Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight. J Transl Med. 2020 Nov 11;18(1):428.
   PubMed Web of Science ®Google Scholar
• Padfield E, Ellis HP, Kurian KM. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol. 2015;5:5.
   PubMed Web of Science ®Google Scholar
• Kwatra MM. A rational approach to target the epidermal growth factor receptor in glioblastoma. Curr Cancer Drug Targets. 2017;17(3):290–296.
   PubMed Web of Science ®Google Scholar
• Ren PP, Li M, Li TF, et al. Anti-EGFRvIII chimeric antigen receptor-modified T cells for adoptive cell therapy of glioblastoma. Curr Pharm Des. 2017;23(14):2113–2116.
   PubMed Web of Science ®Google Scholar
• Luzzi S, Giotta Lucifero A, Brambilla I, et al. Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges. Acta Biomed. 2020 Jun 30;91(7–s):18–31.
   PubMedGoogle Scholar
• Vora P, Venugopal C, Salim SK, et al. The rational development of CD133-Targeting immunotherapies for glioblastoma. Cell Stem Cell. 2020 Jun 4;26(6):832–844.e6.
   PubMed Web of Science ®Google Scholar
• Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 2000 Mar 1;60(5):1168–1172.
   PubMed Web of Science ®Google Scholar
• Brown CE, Starr R, Aguilar B, et al. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res. 2012 Apr 15;18(8):2199–2209.
   PubMed Web of Science ®Google Scholar
• Tu M, Wange W, Cai L, et al. IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway. Tumour Biol. 2016 Nov;37(11):14701–14709.
   PubMedGoogle Scholar
• Correction: glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis. PLoS One. 2018;13(9):e0204463.
   PubMed Web of Science ®Google Scholar
• Lupu R, Colomer R, Kannan B, et al. Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2287–2291.
   PubMed Web of Science ®Google Scholar
• Koka V, Potti A, Forseen SE, et al. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol. 2003 Aug;26(4):332–335.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, et al. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 1;3(8):1094–1101.
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995 Jul;19(3):183–232.
   PubMed Web of Science ®Google Scholar
• Sugawa N, Ekstrand AJ, James CD, et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8602–8606.
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309–4313.
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Suki D, Yang D, et al. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med. 2005 Oct;19(3):38.
   Web of Science ®Google Scholar
• Majc B, Novak M, and Kopitar-Jerala N, et al. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development. Cells. 2021 Jan 29;10(2):265.
   Web of Science ®Google Scholar
• Klein E, Hau AC, Oudin A, et al. Glioblastoma organoids: pre-clinical applications and challenges in the context of immunotherapy. Front Oncol. 2020;10:604121.
   PubMed Web of Science ®Google Scholar
• Olson B, Li Y, Lin Y, et al. Mouse Models for Cancer Immunotherapy Research. Cancer Discov. 2018 Nov;8(11):1358–1365.
   PubMed Web of Science ®Google Scholar
• Salinas RD, Durgin JS, O’Rourke DM. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. CNS Drugs. 2020 Feb;34(2):127–145.
   PubMed Web of Science ®Google Scholar
• Joo KM, Kim J, Jin J, et al. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 2013 Jan 31;3(1):260–273.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Shuen TWH, Toh TB, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut. 2018 Oct;67(10):1845–1854.
   PubMed Web of Science ®Google Scholar
• Lin S, Huang G, Cheng L, et al. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs. 2018 Nov-Dec;10(8):1301–1311.
   PubMed Web of Science ®Google Scholar
• Ali N, Flutter B, Sanchez Rodriguez R, et al. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype. PLoS One. 2012;7(8):e44219.
   PubMed Web of Science ®Google Scholar
• Kahlon KS, Brown C, Cooper LJ, et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004 Dec 15;64(24):9160–9166.
   PubMed Web of Science ®Google Scholar
• Ohno M, Natsume A, Ichiro Iwami K, et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci. 2010 Dec;101(12):2518–2524.
   PubMed Web of Science ®Google Scholar
• Miao H, Choi BD, Suryadevara CM, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One. 2014;9(4):e94281.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Scholler J, Ohkuri T, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18;7(275):275ra22.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Choi BD, Sanchez-Perez L, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014 Feb 15;20(4):972–984.
   PubMed Web of Science ®Google Scholar
• Giotta Lucifero A, Luzzi S, Brambilla I, et al. Innovative therapies for malignant brain tumors: the road to a tailored cure. Acta Biomed. 2020 Jun 30;91(7–s):5–17.
   PubMedGoogle Scholar
• Choi BD, Yu X, Castano AP, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019 Sep;37(9):1049–1058.
   PubMed Web of Science ®Google Scholar
• Ravanpay AC, Gust J, Johnson AJ, et al. EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget. 2019 Dec 17;10(66):7080–7095.
   PubMedGoogle Scholar
• Chen M, Sun R, Shi B, et al. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice. Biomed Pharmacother. 2019;113:108734.
   PubMed Web of Science ®Google Scholar
• Agliardi G, Liuzzi AR, Hotblack A, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021 Jan 19;12(1):444.
   PubMed Web of Science ®Google Scholar
• Jin L, Tao H, Karachi A, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019 Sep 5;10(1):4016.
   PubMed Web of Science ®Google Scholar
• Tang X, Zhao S, Zhang Y, et al. B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma. Mol Ther Oncolytics. 2019 Sep 27;14:279–287.
   PubMed Web of Science ®Google Scholar
• Wang D, Starr R, and Chang WC, et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med. 2020 Mar 4;12(533):eaaw2672.
   Web of Science ®Google Scholar
• Daher M, Melo Garcia L, Li Y, et al. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunology. 2021;10(4):e1274.
   PubMed Web of Science ®Google Scholar
• Akhavan D, Alizadeh D, Wang D, et al. CAR T cells for brain tumors: lessons learned and road ahead. Immunol Rev. 2019 Jul;290(1):60–84.
   PubMed Web of Science ®Google Scholar
• Li T, Zhang Y, Peng D, et al. A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy. J Immunother Cancer. 2019 Feb 21;7(1):51.
   PubMedGoogle Scholar
• Georgiadis C, Preece R, Nickolay L, et al. Long terminal repeat CRISPR-CAR-Coupled “Universal” T cells mediate potent anti-leukemic effects. Mol Ther. 2018 May 2;26(5):1215–1227.
   PubMed Web of Science ®Google Scholar
• Cooper ML, Choi J, Staser K, et al. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018 Sep;32(9):1970–1983.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an Anti-CD19 chimeric antigen receptor induce remissions of B-Cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016 Apr 1;34(10):1112–1121.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2017 Nov;179(4):598–605.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013 Dec 12;122(25):4129–4139.
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol. 2011 Jun;12(6):492–499.
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015 Jun;21(6):581–590.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015 Aug;15(8):486–499.
   PubMed Web of Science ®Google Scholar
• Weber EW, Parker KR, and Sotillo E, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. 2021 Apr 2;372(6537):eaba1786.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tong C, Dai H, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021 Jan 18;12(1):409.
   PubMed Web of Science ®Google Scholar
• Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol. 2003 Mar;4(3):235–240.
   PubMed Web of Science ®Google Scholar
• Mazzone R, Zwergel C, Mai A, et al. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics. 2017;9:59.
   PubMed Web of Science ®Google Scholar
• Doering TA, Crawford A, Angelosanto JM, et al. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity. 2012 Dec 14;37(6):1130–1144.
   PubMed Web of Science ®Google Scholar
• Crawford A, Angelosanto JM, Kao C, et al. Molecular and transcriptional basis of CD4⁺ T cell dysfunction during chronic infection. Immunity. 2014 Feb 20;40(2):289–302.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Paley MA, Kroy DC, Odorizzi PM, et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science. 2012 Nov 30;338(6111):1220–1225.
   PubMed Web of Science ®Google Scholar
• Quigley M, Pereyra F, Nilsson B, et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010 Oct;16(10):1147–1151.
   PubMed Web of Science ®Google Scholar
• Sen DR, Kaminski J, Barnitz RA, et al. The epigenetic landscape of T cell exhaustion. Science. 2016 Dec 2;354(6316):1165–1169.
   PubMed Web of Science ®Google Scholar
• Pandiyan K, You JS, Yang X, et al. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res. 2013 Apr;41(7):3973–3985.
   PubMed Web of Science ®Google Scholar
• Yu B, Zhang K, Milner JJ, et al. Epigenetic landscapes reveal transcription factors that regulate CD8(+) T cell differentiation. Nat Immunol. 2017 May;18(5):573–582.
   PubMed Web of Science ®Google Scholar
• Schoenborn JR, Dorschner MO, Sekimata M, et al. Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon-gamma. Nat Immunol. 2007 Jul;8(7):732–742.
   PubMed Web of Science ®Google Scholar
• Finney OC, Brakke HM, Rawlings-Rhea S, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019 May 1;129(5):2123–2132.
   PubMed Web of Science ®Google Scholar
• Li Y, Wu D, Yang X, et al. Immunotherapeutic Potential of T Memory Stem Cells. Front Oncol. 2021;11:723888.
   PubMedGoogle Scholar
• Biasco L, Izotova N, Rivat C, et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat Cancer. 2021 Jun 2;6:629–642.
   PubMedGoogle Scholar
• Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009 Apr 1;69(7):3077–3085.
   PubMed Web of Science ®Google Scholar
• Chang AL, Miska J, Wainwright DA, et al. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Cancer Res. 2016 Oct 1;76(19):5671–5682.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu T, Yang N, et al. Hypoxia and macrophages promote glioblastoma invasion by the CCL4-CCR5 axis. Oncol Rep. 2016 Dec;36(6):3522–3528.
   PubMed Web of Science ®Google Scholar
• Pan Y, Smithson LJ, Ma Y, et al. Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival. Oncotarget. 2017 May 16;8(20):32977–32989.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Lagman C, Chung LK, et al. Insights into CCL21’s roles in immunosurveillance and immunotherapy for gliomas. J Neuroimmunol. 2017 Apr 15;305:29–34.
   PubMed Web of Science ®Google Scholar
• Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011 Jul 15;17(14):4719–4730.
   PubMed Web of Science ®Google Scholar
• Craddock JA, Lu A, Bear A, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct;33(8):780–788.
   PubMed Web of Science ®Google Scholar
• Evgin L, and Vile RG. Parking CAR T Cells in Tumours: oncolytic Viruses as Valets or Vandals? Cancers (Basel). 2021 Mar 5;13(5):1106.
   PubMed Web of Science ®Google Scholar
• Nishio N, Diaconu I, Liu H, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014 Sep 15;74(18):5195–5205.
   PubMed Web of Science ®Google Scholar
• Newick K, O’Brien S, Moon E, et al. CAR T cell therapy for solid tumors. Annu Rev Med. 2017 Jan 14;68:139–152.
   PubMed Web of Science ®Google Scholar
• Brown DV, Stylli SS, Kaye AH, et al. Multilayered Heterogeneity of Glioblastoma Stem Cells: Biological and Clinical Significance. Adv Exp Med Biol. 2019;1139:1–21.
   PubMed Web of Science ®Google Scholar
• Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016 Aug 1;126(8):3036–3052.
   PubMed Web of Science ®Google Scholar
• Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018 Jan;24(1):20–28.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Mackall CL. Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018 Oct;8(10):1219–1226.
   PubMed Web of Science ®Google Scholar
• Wykosky J, Gibo DM, Stanton C, et al. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res. 2005 Oct;3(10):541–551.
   PubMed Web of Science ®Google Scholar
• Yi Z, Prinzing BL, Cao F, et al. Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma. Mol Ther Methods Clin Dev. 2018 Jun 15;9:70–80.
   PubMed Web of Science ®Google Scholar
• Chow KK, Naik S, Kakarla S, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013 Mar;21(3):629–637.
   PubMed Web of Science ®Google Scholar
• Lin Q, Ba T, Ho J, et al. First-in-human trial of EphA2-redirected CAR T-Cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose. Front Oncol. 2021;11:694941.
   PubMed Web of Science ®Google Scholar
• Sorokin M, Kholodenko I, and Kalinovsky D, et al. RNA sequencing-based identification of ganglioside GD2-positive cancer phenotype. Biomedicines. 2020 May 30;8(6):142.
   Web of Science ®Google Scholar
• Mount CW, Majzner RG, Sundaresh S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med. 2018 May;24(5):572–579.
   PubMed Web of Science ®Google Scholar
• Golinelli G, Grisendi G, Prapa M, et al. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther. 2020 Aug;27(7–8):558–570.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Luther N, Ibrahim GM, et al. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol. 2013 Feb;111(3):257–264.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Theruvath JL, Nellan A, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019 Apr 15;25(8):2560–2574.
   PubMed Web of Science ®Google Scholar
• Nguyen P, Okeke E, Clay M, et al. Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR.CD28ζ T cells. Mol Ther Oncolytics. 2020 Sep 25;18:202–214.
   PubMed Web of Science ®Google Scholar
• Dardevet L, Rani D, Aziz TA, et al. Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion. Toxins (Basel). 2015 Mar 27;7(4):1079–1101.
   PubMed Web of Science ®Google Scholar
• Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol. 2016 May;23(11):47–76.
   Google Scholar
• Maccalli C, Rasul KI, Elawad M, et al. The role of cancer stem cells in the modulation of anti-tumor immune responses. Semin Cancer Biol. 2018 Dec;53:189–200.
   PubMed Web of Science ®Google Scholar
• Steinbichler TB, Dudás J, Skvortsov S, et al. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018 Dec;53:156–167.
   PubMed Web of Science ®Google Scholar
• Lathia JD, Mack SC, Mulkearns-Hubert EE, et al. Cancer stem cells in glioblastoma. Genes Dev. 2015 Jun 15;29(12):1203–1217.
   PubMed Web of Science ®Google Scholar
• Behnan J, Finocchiaro G, Hanna G. The landscape of the mesenchymal signature in brain tumours. Brain. 2019 Apr 1;142(4):847–866.
   PubMedGoogle Scholar
• Zhu X, Prasad S, Gaedicke S, et al. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget. 2015 Jan 1;6(1):171–184.
   PubMed Web of Science ®Google Scholar
• Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018 Aug;560(7718):382–386.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012 May 3;119(18):4133–4141.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154.
   PubMed Web of Science ®Google Scholar
• Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017 Feb 23;129(8):1039–1041.
   PubMed Web of Science ®Google Scholar
• Weiss T, Weller M, Guckenberger M, et al. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 2018 Feb 15;78(4):1031–1043.
   PubMed Web of Science ®Google Scholar
• Heczey A, Louis CU, Savoldo B, et al. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 Sep 6;25(9):2214–2224.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Tashiro H, Omer B, et al. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells. Clin Cancer Res. 2017 Jul 15;23(14):3499–3509.
   PubMed Web of Science ®Google Scholar
• Li S, Siriwon N, Zhang X, et al. Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors. Clin Cancer Res. 2017 Nov 15;23(22):6982–6992.
   PubMed Web of Science ®Google Scholar
• Hurton LV, Singh H, Najjar AM, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A. 2016 Nov29;113(48):E7788–e7797.
   PubMed Web of Science ®Google Scholar
• Hu B, Ren J, Luo Y, et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 2017 Sep 26;20(13):3025–3033.
   PubMed Web of Science ®Google Scholar
• Avanzi MP, van Leeuwen GD, Li X, et al. IL-18 secreting CAR T cells enhance cell persistence, induce prolonged B cell aplasia and eradicate CD19+ tumor cells without need for prior conditioning. Blood. 2016;128(22):816.
   PubMed Web of Science ®Google Scholar
• Wang L, Yao R, Zhang L, et al. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity. Int Immunopharmacol. 2019 May;70:498–503.
   PubMed Web of Science ®Google Scholar
• Li L, Zhu X, Qian Y, et al. Chimeric antigen receptor T-Cell therapy in glioblastoma: current and future. Front Immunol. 2020;11:594271.
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005 Apr 1;105(7):2862–2868.
   PubMed Web of Science ®Google Scholar
• Suryadevara CM, Desai R, Abel ML, et al. Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology. 2018;7(6):e1434464.
   PubMed Web of Science ®Google Scholar
• Flynn JP, O’Hara MH, Gandhi SJ. Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e. CART). Transl Lung Cancer Res. 2017 Apr;6(2):159–168.
   PubMed Web of Science ®Google Scholar
• Minn I, Rowe SP, Pomper MG. Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. Lancet Oncol. 2019 Aug;20(8):e443–e451.
   PubMed Web of Science ®Google Scholar
• Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020 Jan;20(1):26–41.
   PubMed Web of Science ®Google Scholar
• Portella L, Scala S. Ionizing radiation effects on the tumor microenvironment. Semin Oncol. 2019 Jun;46(3):254–260.
   PubMed Web of Science ®Google Scholar
• Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006 May 15;203(5):1259–1271.
   PubMed Web of Science ®Google Scholar
• Spiotto M, Fu YX, and Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol. 2016 Sep;1(3):EAAG1266.
   PubMed Web of Science ®Google Scholar
• Lugade AA, Sorensen EW, Gerber SA, et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008 Mar 1;180(5):3132–3139.
   PubMed Web of Science ®Google Scholar
• DeSelm C, Palomba ML, Yahalom J, et al. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther. 2018 Nov 7;26(11):2542–2552.
   PubMed Web of Science ®Google Scholar
• Yang J, Yan J, Targeting LB. VEGF/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978.
   PubMed Web of Science ®Google Scholar
• Bocca P, Di Carlo E, Caruana I, et al. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model. Oncoimmunology. 2017;7(1):e1378843.
   PubMed Web of Science ®Google Scholar
• Shen SH, Woroniecka K, Barbour AB, et al. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opin Biol Ther. 2020 Jun;20(6):579–591.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016 Aug 1;126(8):3130–3144.
   PubMed Web of Science ®Google Scholar
• Chen N, Morello A, Tano Z, et al. CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. Oncoimmunology. 2017;6(2):e1273302.
   PubMed Web of Science ®Google Scholar
• Liu X, Ranganathan R, Jiang S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016 Mar 15;76(6):1578–1590.
   PubMed Web of Science ®Google Scholar
• Ajina A, Maher J. Prospects for combined use of oncolytic viruses and CAR T-cells. J Immunother Cancer. 2017 Nov21;5(1):90.
   PubMedGoogle Scholar
• Twumasi-Boateng K, Pettigrew JL, Kwok YYE, et al. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer. 2018 Jul;18(7):419–432.
   PubMed Web of Science ®Google Scholar
• Li H, Ding J, Lu M, et al. CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal cancer models. J Immunother. 2020 Jan;43(1):16–28.
   PubMed Web of Science ®Google Scholar
• Wu X, Luo H, Shi B, et al. Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma. Mol Ther. 2019 Aug 7;27(8):1483–1494.
   PubMed Web of Science ®Google Scholar
• Cui J, Wang H, and Medina R, et al. Inhibition of PP2A with LB-100 enhances efficacy of CAR-T cell therapy against glioblastoma. Cancers (Basel). 2020 Jan 6;12(1):139.
   Web of Science ®Google Scholar
• Zhang F, Wen Y, Guo X. CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet. 2014 Sep 15;23(R1):R40–6.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Y, Cheng C, et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 2017 Jan;27(1):154–157.
   PubMed Web of Science ®Google Scholar
• Ren J, Liu X, Fang C, et al. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clin Cancer Res. 2017 May 1;23(9):2255–2266.
   PubMed Web of Science ®Google Scholar
• Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018 Jun;24(6):731–738.
   PubMed Web of Science ®Google Scholar
• Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019 Aug;15(8):813–822.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+: CD8+composition in adult B cell ALL patients. J Clin Invest. 2016 Jun 1;126(6):2123–2138.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-Term Follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):449–459.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory Large B-Cell lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hay KA, Hanafi LA, et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol. 2017 Sep 10;35(26):3010–3020.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-Cell lymphomas. N Engl J Med. 2017 Dec 28;377(26):2545–2554.
   PubMed Web of Science ®Google Scholar
• Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021 Jan;32(1):34–48.
   PubMed Web of Science ®Google Scholar
• Chou CK, Turtle CJ. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther. 2020 Jun;20(6):653–664.
   PubMed Web of Science ®Google Scholar
• Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018 Aug;23(8):943–947.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan;15(1):47–62.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625–638.
   PubMed Web of Science ®Google Scholar
• Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019 Jun;37(Suppl 1):48–52.
   PubMed Web of Science ®Google Scholar
• Varadarajan I, Lee DW. Management of T-Cell engaging immunotherapy complications. Cancer J. 2019 May/Jun;25(3):223–230.
   PubMed Web of Science ®Google Scholar
• Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci. 2006 Jan;63(1):60–72.
   PubMed Web of Science ®Google Scholar
• Liu S, Deng B, Yin Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020 Feb 6;10(2):15.
   PubMed Web of Science ®Google Scholar
• Topp M, Van Meerten T, Houot R, et al. Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory Large B Cell lymphoma. Blood. 2019;134(Supplement_1):243.
   Google Scholar
• Gutierrez C, Brown ART, Herr MM, et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J Crit Care. 2020;58:58–64.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188–195.
   PubMed Web of Science ®Google Scholar
• Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018 Jun;24(6):739–748.
   PubMed Web of Science ®Google Scholar
• Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med. 2018 May;66(2):50–52.
   PubMed Web of Science ®Google Scholar
• Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017 Dec;7(12):1404–1419.
   PubMed Web of Science ®Google Scholar
• Santomasso BD, Park JH, Salloum D, et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2018 Aug;8(8):958–971.
   PubMed Web of Science ®Google Scholar
• Siegler EL, Kenderian SS. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Front Immunol. 2020;11:1973.
   PubMed Web of Science ®Google Scholar
• Mackall CL, Miklos DB. CNS endothelial cell activation emerges as a driver of CAR T cell-associated neurotoxicity. Cancer Discov. 2017 Dec;7(12):1371–1373.
   PubMed Web of Science ®Google Scholar
• The Lancet O. CAR T-cell therapy for solid tumours. Lancet Oncol. 2021 Jul;22(7):893.
   PubMed Web of Science ®Google Scholar
• Menger L, Gouble A, Marzolini MA, et al. TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Blood. 2015 Dec 24;126(26):2781–2789.
   PubMed Web of Science ®Google Scholar
• Migliorini D, Dietrich PY, Stupp R, et al. CAR T-Cell Therapies in Glioblastoma: A First Look. Clin Cancer Res. 2018 Feb 1;24(3):535–540.
   PubMed Web of Science ®Google Scholar
• Nellan A, Cml M, Cruz Garcia R, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood. 2018;132(6):662–666.
   PubMed Web of Science ®Google Scholar
• Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 May 16;133(20):2212–2221.
   PubMed Web of Science ®Google Scholar
• Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. Trends Immunol. 2019 Feb;40(2):142–158.
   PubMed Web of Science ®Google Scholar
• Haspels HN, Rahman MA, Joseph JV, et al. Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions. Front Immunol. 2018;9:1345.
   PubMed Web of Science ®Google Scholar
• Burger MC, Zhang C, Harter PN, et al. CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy. Front Immunol. 2019;10:2683.
   PubMed Web of Science ®Google Scholar
• Ramanathan A, Lorimer IAJ. Engineered cells as glioblastoma therapeutics. Cancer Gene Ther. 2021 Mar 22.
   PubMed Web of Science ®Google Scholar
• Murakami T, Nakazawa T, Natsume A, et al. Novel human NK cell line carrying CAR targeting EGFRvIII induces antitumor effects in glioblastoma cells. Anticancer Res. 2018 Sep;38(9):5049–5056.
   PubMed Web of Science ®Google Scholar
• Han J, Chu J, Keung Chan W, et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of Glioblastoma and patient-derived glioblastoma stem cells. Sci Rep. 2015 Jul;9(5):11483.
   Google Scholar
• Genßler S, Burger MC, Zhang C, et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology. 2016 Apr;5(4):e1119354.
   PubMed Web of Science ®Google Scholar
• Müller N, Michen S, Tietze S, et al. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma. J Immunother. 2015 Jun;38(5):197–210.
   PubMed Web of Science ®Google Scholar
• Zhang C, Burger MC, Jennewein L, et al. ErbB2/HER2-specific NK cells for targeted therapy of Glioblastoma. J Natl Cancer Inst. 2016;108(5):May.
   Google Scholar
• Gatto L, Nunno VD, Franceschi E, et al. Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward. Immunotherapy. 2021 Jun 3.
   Web of Science ®Google Scholar
• Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020 Aug;38(8):947–953.
   PubMed Web of Science ®Google Scholar
• Massari F, Rizzo A, Mollica V, et al. A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? Future Oncol. 2021 May;17(15):1839–1841.
   PubMed Web of Science ®Google Scholar
• Santoni M, Massari F, Montironi R, et al. Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. Biochim Biophys Acta Rev Cancer. 2021 Apr 29;1876(1):188547
   PubMed Web of Science ®Google Scholar